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he has now had an unexpected and signiﬁcant progression.
The role of sickle cell trait in his progression is unclear.
Though bone marrow transplantation may be curative ther-
apy for sickle cell disease, it may not halt the progression in
all patients, especially those with severe disease.299
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Introduction: Leukocyte adhesion deﬁciency type I(LAD-I) is
a congenital disorder that is usually fatal during ﬁrst decade
of life due to recurrent life-treating bacterial infection. Allo-
geneic hematopoietic stem cell transplantation (HSCT) has
been accepted as one of the only curative treatment for LAD-
I. The conditioning regimen used for HSCT in LAD-I is still a
controversial issue.
Patients and Methods: Between 2007 and 2014, 20 pedi-
atric patients(12 female) with conﬁrmed LAD-I who were
referred to our center underwent HSCT. The median age at
the time of diagnosis and transplantation was 11.5 months
(range:1month-5years) and 24.5 months (range:4months-
14years), respectively. Patients underwent HSCT from
matched related donor (n¼15), mismatched related or un-
related donor(n¼3), unrelated fully matched donor(n¼1)
and haploidentical relative donor(n¼1). Sources of stem cells
were peripheral blood(n¼10), bone marrow(n¼8) and cord
blood(n¼2). All patients were admitted several times due to
infection, prior to HSCT. The study utilized reduced-intensity
conditioning(RIC) regimen consisting of Fludarabine,
Melphalan and ATG. Cyclosporine and Methylprednisolone
were used as graft-versus-host disease (GvHD) prophylaxis
regimen.
Result: All but one patient engrafted. The median time for
ANC and platelet engraftment was 12 days (range: 10-
23days) and 15 days (range: 10-32days), respectively. With a
median follow-up of 43 months (range: 6-85months), 7 pa-
tients showed acute GvHD (2 grade I-II, 5 grade III-IV), while2 patients developed limited chronic GvHD. The 4-year OS
and DFS was 80% (95%CI: 54-92%). Among 19 patients who
showed engraftment, 9 with full chimerism and 7 with
mixed chimerism are still alive and disease free. Five patients
expired due to GvHD and infection.
Conclusion: As pre-transplant infections in LAD-I lead to rise
in mortality rate, the use of myeloablative conditioning
regimen may result in increased risk of mortality. Using less-
toxic regimen with RIC seems to be highly effective and will
improve manifestation of LAD-I with either full or mixed
chimerism.300
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For many years the standard conditioning regimen for chil-
dren with myeloid malignancies and certain non-malignant
diseases, such as sickle cell disease, was myeloablative
busulfan combined with high dose cyclophosphamide.
Regimen-related toxicity remains a concern, with sinusoidal
obstructive syndrome (SOS) occurring in up to 28% of pa-
tients (Ozkaynak et al, BMT 1991). The substitution of ﬂu-
darabine for cyclophosphamide led to less toxicity and better
outcomes in adult patients (Andersson et al, BBMT 2008), but
there is little data for ﬂudarabine/myeloablative busulfan
(FluBu4) in children.
We report the outcomes for 23 consecutive pediatric patients
(median 7 years old, range 0-17) who underwent allogeneic
BMT following FluBu4 conditioning between December 2006
and May 2014. The indications for transplant were acute
leukemia (N¼12), MDS/MPD (N¼7), CML (N¼1), and non-
malignant disorders (N¼3). There were 17 unrelated donors
and 6 sibling donors. Stem cell sources were marrow (N¼15)
or cord blood (N¼8). All cord blood transplants were
matched at 4-6/6 HLA-loci. Marrow grafts were allele
matched at 8/8 HLA-loci in 13/15 patients; 2 were 7/8
matched. The conditioning regimen consisted of once daily
ﬂudarabine 40 mg/m2 (1.3 mg/kg for patients <10kg) and
pharmacokinetically-adjusted busulfan targeting a CSS of
600-900 mcg/L daily on days -5 to -2. Thirteen patients at
higher risk for graft failure (HLA-mismatched grafts, cord
blood or non-malignant disease) received either anti-
thymocyte globulin (N¼8) or low dose (2-4 Gy) radiation
(N¼5). All patients received a calcineurin inhibitor for GVHD
prophylaxis along with short-coursemethotrexate (N¼15) or
MMF (N¼8) per institutional guidelines. Notable non-GVHD
toxicities developed in two patients (9%). There was one case
of self-limited moderate SOS. One patient experienced fatal
primary graft failure that occurred after receiving an HLA-
mismatched cord blood graft for PNH; all other patients
(96%) engrafted neutrophils (median 14 days, range 12-26).
There were no cases of idiopathic pneumonia syndrome.
Acute GVHD grade II-IV developed in 4 patients (17%) at a
median onset of 26 days (range 9-139 days). Two patients
developed BK virus-associated hemorrhagic cystitis while on
high-dose steroids for acute GVHD. The cumulative incidence
of relapse at 2 years for patients transplanted for malignancy
was 31%; relapse occurred at a median of 45 days post-
transplant (range 22-201 days). Non-relapse mortality and
overall survival at 2 years are 14% and 63%, respectively
Figure 1.
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sibling and alternative donors, a FluBu4 backbone  ATG or
low dose radiation was an exceptionally well-tolerated
conditioning regimen that resulted in prompt and reliable
engraftment. Relapse rates and overall survival were similar
to those seen with other myeloablative regimens.301
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With the absence of speciﬁc clinical practice guidelines for
the management of febrile pediatric HSCT patients, many
institutions apply oncology febrile neutropenia guidelines to
pediatric HSCT patients. Recent guidelines regarding the
management of febrile neutropenia in pediatric oncology
patients have questioned the role of sinus CT in their eval-
uation. We sought to determine the predictive factors for
positive ﬁndings on sinus CT and their impact on manage-
ment of febrile pediatric allo-HSCT patients in the ﬁrst year
after transplant. We conducted a retrospective chart review
from 7/1/2007 through 6/30/13. There were 41 febrile epi-
sodes from 37 patients that included sinus CT in the evalu-
ation.19 of the 41 episodes (46%) had positive ﬁndings on the
sinus CT. There was no statistically signiﬁcant difference
between the positive sinus CT and the negative sinus CT
groups with regards to diagnosis, disease status, preparative
regimen, HLA matching/graft source, GVHD, GVHD treat-
ment, presence of NG or ETT, positive blood or urine culture,
or positive ﬁndings on the pre-HSCT sinus CT. The median
time from onset of fever to the sinus CT in the positive sinus
CT group and the negative sinus CT group was not signiﬁ-
cantly different using the log-rank test (256 hrs and 170 hrs,
p¼0.14). Median ANC and APC at onset of fever were signif-
icantly higher in the positive sinus CT group compared to the
negative sinus CT group using the Wilcoxon rank sum test
(2.470109/L and 3.050 109/L versus 0.775109/L and 1.060 109/
L , p¼0.03 and 0.04). 16% of episodes with a positive sinus CT
had no other source of infection identiﬁed, but no episodes
had changes to the pharmacotherapy regimen solely based
on a positive sinus CT. One patient did undergo bilateral
endoscopic maxillary antrostomies and anterior ethmoi-
dostomies, and cultures were positive for Candida glabrata.Sinus CT has a minimal impact on the management of febrile
pediatric allo-HSCT recipients and should be examined in
larger multi-center groups to help develop practice guide-
lines.302
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Alemtuzumab (humanized CD52-monoclonal antibody), a
potent T cell inhibitor, is often included in reduced-intensity
conditioning (RIC) regimens. Modeled on the successes of
such regimens, newer alemtuzumab-containing RIC regi-
mens are being increasingly used for patients with hemo-
globinopathies. We retrospectively reviewed the possible
impact of “late” alemtuzumab (i.e., administered on days -10
through -8) with respect to engraftment and acute/chronic
GvHD in nine pediatric patients (median age 10 y, range 5.1-
18.6yrs)with sickle cell disease who underwent stem cell
transplantation from HLA-matched sibling donors. All pa-
tients received alemtuzumab 10 mg IV daily on days-10
through-8, ﬂudarabine 35 mg/m2/day IV on days-7 to-4, and
melphalan 70 mg/m2 IV on day -3 and day -2. Alemtuzumab
was given relatively close to the day of transplant with intent
to diminish the incidence of graft versus host disease. Eight
out of 9 patients received marrow and 1 patient received
marrow and cord blood. Median nucleated cell dose was 2.3
x 108/kg (Range: 1.46-4.3), with median CD34 cell dose of 1.6
x 106/kg (range: 0.9-5.5). Median time to neutrophil and
platelet engraftment was 15.5 and 36 days, respectively, in
our study. All of the patients received the GvHD prophylactic
regimen comprising of Cyclosporine and Mycophenolate,
both beginning on day -1 of transplant. All patients have
been followed a minimum of 3.5yrs post-transplant.
One patient developed mild acute GvHD of the skin and
another developed limited chronic skin GvHD (taken off
